The influence of ocular surface diseases in the management of glaucoma;Influence des pathologies de la surface oculaire sur le traitement du glaucome

Journal Francais d'Ophtalmologie

Volumn 34, Issue 4, 2011, Pages 230-237

  Van Went, C ^a   Brasnu, E ^a   Hamard, P ^a   Baudouin, C ^a,b,c,d   Labbe A ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d INSERM   (France)

Author keywords

Conjunctiva; Cornea; Glaucoma; Ocular surface disease; Preservative; Tear film; Toxicity; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; PRESERVATIVE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG EFFECT; EYE DISEASE; FEMALE; FILTERING OPERATION; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; TRABECULECTOMY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EYE DISEASES; FEMALE; FILTERING SURGERY; FOLLOW-UP STUDIES; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TRABECULECTOMY;

EID: 79954604743     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2010.11.010     Document Type: Article

References (21)

1. R.N. Weinreb, Y. Kitazawa, and G.K. Krieglstein Glaucoma in the 21st century 2000 Mosby international Ltd, Harcourt Health Communications Barcelone, Espagne
2. N. Jaenen, C. Baudouin, P. Pouliquen, G. Manni, A. Figueiredo, and T. Zeyen Ocular symptoms and signs with preserved and preservative-free glaucoma medications Eur J Ophthalmol 173 2007 341 349 (Pubitemid 47056287)
3. E.W. Leung, F.A. Medeiros, and R.N. Weinreb Prevalence of ocular surface disease in glaucoma patients J Glaucoma 17 2008 350 355
4. P.J. Pisella, P. Pouliquen, and C. Baudouin Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication Br J Ophthalmol 86 2002 418 423 (Pubitemid 34293291)
5. J.P. Nordmann, N. Auzanneau, S. Ricard, and G. Berdeaux Vision related quality of life and topical glaucoma treatment side effects Health Qual Life Outcomes 1 2003 75
6. G.F. Schwartz, and H.A. Quigley Adherence and persistence with glaucoma therapy Surv Ophthalmol 53 2008 S57 S68
7. T.J. Zimmerman, S.R. Hahn, L. Gelb, H. Tan, and E.E. Kim The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence J Ocul Pharmacol Ther 25 2009 145 152
8. A. Chawla, J.N. McGalliard, and M. Batterbury Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand 85 2007 464 (Pubitemid 46901501)
9. European-Glaucoma-Society Terminology and guidelines for glaucoma 2003 Editrice DOGMA ed Savona, Italy
10. K.L. Miller, J.G. Walt, D.R. Mink, S. Satram-Hoang, S.E. Wilson, and H.D. Perry Minimal clinically important difference for the Ocular Surface Disease Index Arch Ophthalmol 128 2010 94 101
11. R.M. Schiffman, M.D. Christianson, G. Jacobsen, J.D. Hirsch, and B.L. Reis Reliability and validity of the Ocular Surface Disease Index Arch Ophthalmol 118 2000 615 621 (Pubitemid 30327337)
12. C.B. Camras Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 133 2002 732 [author reply-3]
13. E.J. Higginbotham, J.S. Schuman, I. Goldberg, R.L. Gross, A.M. VanDenburgh, and K. Chen One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension Arch Ophthalmol 120 2002 1286 1293 (Pubitemid 36105433)
14. P.A. Netland, T. Landry, E.K. Sullivan, R. Andrew, L. Silver, and A. Weiner Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 132 2001 472 484 (Pubitemid 32904567)
15. E. Strahlman, R. Tipping, R. Vogel International Dorzolamide Study Group A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol Arch Ophthalmol 113 1995 1009 1016
16. J.S. Schuman, B. Horwitz, N.T. Choplin, R. David, D. Albracht, and K. Chen A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial Arch Ophthalmol 115 1997 847 852
17. M.A. Kass, D.K. Heuer, E.J. Higginbotham, C.A. Johnson, J.L. Keltner, and J.P. Miller The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 2002 701 713 (Pubitemid 34620348)
18. S.E. Moss, R. Klein, and B.E. Klein Prevalence of and risk factors for dry eye syndrome Arch Ophthalmol 118 2000 1264 1268
19. F.S. Ali, and E.K. Akpek Glaucoma and dry eye Ophthalmology 116 2009 1232
20. G. Martone, P. Frezzotti, G.M. Tosi, C. Traversi, V. Mittica, and A. Malandrini An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology Am J Ophthalmol 147 2009 725 735
21. C. Baudouin, A. Labbé, H. Liang, A. Pauly, and F. Brignole-Baudouin Preservatives in eyedrops: the good, the bad and the ugly Prog Retin Eye Res 29 2010 312 334